US 12,295,948 B2
Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment
Vinay K. Jain, Dallas, TX (US); and Bothayna Messahel, Coppell, TX (US)
Assigned to Arog Pharmaceuticals, Inc., Plano, TX (US)
Filed by Arog Pharmaceuticals, Inc., Plano, TX (US)
Filed on Nov. 20, 2023, as Appl. No. 18/513,888.
Application 18/513,888 is a division of application No. 17/830,682, filed on Jun. 2, 2022, granted, now 11,857,546.
Claims priority of provisional application 63/270,887, filed on Oct. 22, 2021.
Prior Publication US 2024/0100040 A1, Mar. 28, 2024
Int. Cl. A61K 31/4709 (2006.01); A61P 35/02 (2006.01); C12Q 1/6886 (2018.01)
CPC A61K 31/4709 (2013.01) [A61P 35/02 (2018.01); C12Q 1/6886 (2013.01); C12Q 2600/156 (2013.01)] 5 Claims
 
1. A method of inhibiting or reducing mutant FLT3 tyrosine kinase activity or expression in a subject suffering from a proliferative disorder comprising:
identifying that the subject discontinued a prior tyrosine kinase inhibitor therapy due to refractory or relapsed proliferative disease;
obtaining a tumor sample from the subject;
measuring expression of a mutated FLT3 or a constitutively active FLT3 mutant in the tumor sample; and
if the subject has the mutated FLT3 or constitutively active FLT3 mutant, administering to the subject a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof, wherein the crenolanib or salt thereof reduces a proliferative disorder burden or prevents proliferative disease progression.